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Abstract
Background and rationale: Motor fatigue and ambulation impairment are prominent clinical features of people with
multiple sclerosis (pMS). We hypothesized that a multimodal and comparative assessment of walking speed on short and
long distance would allow a better delineation and quantification of gait fatigability in pMS. Our objectives were to
compare 4 walking paradigms: the timed 25-foot walk (T25FW), a corrected version of the T25FW with dynamic start
(T25FW
+), the timed 100-meter walk (T100MW) and the timed 500-meter walk (T500MW).
Methods: Thirty controls and 81 pMS performed the 4 walking tests in a single study visit.
Results: The 4 walking tests were performed with a slower WS in pMS compared to controls even in subgroups with
minimal disability. The finishing speed of the last 100-meter of the T500MW was the slowest measurable WS whereas the
T25FW
+ provided the fastest measurable WS. The ratio between such slowest and fastest WS (Deceleration Index, DI) was
significantly lower only in pMS with EDSS 4.0–6.0, a pyramidal or cerebellar functional system score reaching 3 or a
maximum reported walking distance #4000 m.
Conclusion: The motor fatigue which triggers gait deceleration over a sustained effort in pMS can be measured by the WS
ratio between performances on a very short distance and the finishing pace on a longer more demanding task. The absolute
walking speed is abnormal early in MS whatever the distance of effort when patients are unaware of ambulation
impairment. In contrast, the DI-measured ambulation fatigability appears to take place later in the disease course.
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Introduction
Multiple sclerosis (MS) is a chronic multifocal disease of the
CNS, which produces a wide range of neurological deficits.
Ambulation impairment is recognized as a prominent feature of
disability in MS, both by physicians and people with MS (pMS)
[1]. The mechanisms underlying this locomotor impairment
remain partially elusive. Besides functional system neurological
deficits observed in the course of MS, it has been hypothesized that
MS related motor fatigue can also impede gait performances [2].
In this context, motor fatigue is defined as the gradual decline of
the maximal muscle strength during a constant mild to moderate
physical exercise. Evaluation of ambulation limitation plays a
central role in clinical scales [3] and composite outcome measures
[4,5], which are used in the routine clinical practice and
randomized clinical trials. The quantification of gait performances
in MS remains usually limited to the simple anamnestic recall of
the maximum reported walking distance (MrWD) [3], the
stopwatch measurement of walking speed on short distance
walking tests [4,5] through various settings and methodologies
[6–11], and the measurement of the maximum distance performed
in a given time [12]. In contrast to maximum walking distance or
maximum walking time, walking speed (WS) is believed to be a
more stable parameter, which is less day-to-day variable and can
be extracted from various walking paradigms [13,14]. Only few
studies have investigated the behavior of pMS’ performances on
longer distance walking tests, with variable results and method-
ologies, as well as small population samples [2,12]. Gait is a
complex motor behaviour that can only be roughly disentangled
by a single walking test and we previously hypothesized that a
multimodal walking assessment of gait in pMS would allow a
better delineation and quantification of functional gait impairment
in MS [7].
Since the onset of permanent gait limitations has often been
conceived as a late process in the course of the disease, ambulation
performances are only taken into account beyond the score of 4.0
in the Expanded Disability Status Scale (EDSS) [3]. However,
several studies have suggested that the restriction of ambulation
performances occurs much earlier than previously considered [15–
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e3474417], but the precise timing and the extent of such limitations have
been scarcely investigated.
In this work, we developed a 500-meter walking test to evaluate
the mean WS of pMS in a demanding distance-based effort in
comparison to the conventional short distance 25-foot test in a
similar ‘‘as fast as possible’’ paradigm. Our objectives were (i) to
determine the range of performances of pMS in this long-distance
walking modality, (ii) to study the deceleration of the WS over this
500-meter distance in different subsets of pMS stratified according
to their global EDSS, functional system (FS) scores according to
Kurtzke and MrWD below or above the 4000 m milestone. These
results emphasized that deceleration over the distance of a
demanding ambulation test may be a valuable tool to assess
locomotor fatigability in MS.
Methods
Ethics Statement
The ‘‘Comite ´ d’Ethique hospitalo-facultaire’’ of the CHU of
Lie `ge approved the study procedure and written informed consent
was received from all participants.
Methods
A total of 81 subjects with a diagnosis of relapsing–remitting or
progressive MS according to the McDonald criteria [18] and a
MrWD$500 m, and 30 weight- and sex-matched healthy
volunteers used as a control group were enrolled in the study.
pMS who had an EDSS from 4.5 to 6.0 were allowed to perform
the walk tests using ambulatory assistive devices in case they would
usually need it to walk the distance of 500 m or more. In such
conditions (n=9), the only requirement was that they were asked
to use the same device for all tests. Ankle–foot orthosis was
permitted if worn from onset for all evaluations. pMS who had
experienced clinically disabling MS exacerbations with or without
corticosteroid treatment within the last 3 months before study
enrollment were excluded. Since it was previously shown that the
time of the day does not interfere with ambulation outcome
performances despite changes in subjective fatigue [14], pMS were
tested at random periods of the day at their most convenient time.
pMS and healthy controls performed a multimodal walking
assessment that comprised 4 tests, in the following order : the
Timed 25-Foot Walk Test (T25FW, performed twice), a corrected
version of the T25FW with a dynamic start (T25FW
+, performed
twice [10]), the Timed 100-Meter Walk Test (T100MW [7]), and
the Timed 500-Meter Walk Test (T500MW). A period of rest of
15 minutes was allowed between each test to minimize interfer-
ence due to potential test-related fatigue, and all demanding
physical activities (such as rehabilitation sessions) were suspended
in the last 24 hours prior to the assessment. Our subjects did not
report any increased sense of subjective fatigue before starting a
new test, especially before the last and most demanding T500MW.
A slight worsening of the absolute results due to an increased
motor fatigue in the T500MW cannot be excluded but this
methodological bias was identical for all subjects.
All assessments were made by a certified MS nurse (PC) or by a
physical therapist in charge of patients’ rehabilitation programs
(PG). EDSS scores were all collected by a certified EDSS rater (RP
or SB).
The MrWD was evaluated as follows: control healthy volunteers
all reported a MrWD superior to 4000 m, which was considered
as ‘‘unlimited’’. pMS were asked whether they had the feeling that
during the past 4 weeks their average walking performance had
been unlimited and whether they thought they could walk for
4000 m or more without aid or rest. If they answered ‘‘yes’’, they
were considered to have an ‘‘unlimited’’ MrWD (i.e. $4000 m).
pMS who considered themselves unable to walk 4000 m without
aid or rest were asked to evaluate as accurately as possible their
MrWD, which was defined as the maximum distance they thought
they could walk without rest, and over which they would estimate
they have a high risk of falling in case they would go on for a few
meters more.
The T25FW was performed according to the published
standardized instructions [4,5]. The T25FW
+ was also strictly
following the guidelines of the T25FW [4,5], except that the
subjects were allowed to take a 3 meters run-up before the starting
line [10]. This run-up was clearly demarcated on the ground. In
order to minimize test-retest variability, the mean value of the two
tests was used in the analysis of the T25FW and the T25FW
+.
The T500MW was performed as 5 non-stop consecutive laps of
the same path that served for the T100MW, as previously
described [19], where interval times were recorded at each 100 m.
The T100MW and T500MW were performed in a 3 m width
corridor, devoid of obstacles. Running was prohibited. The subject
was directed just behind the starting line and then instructed as
follows: ‘‘I’d like you to walk this 100 (or 500) meter distance as
quickly as possible, but safely. Do not slow down until after you’ve
passed the finish line. Ready? Go.’’ Timing started when the lead
foot crossed the starting line. The examiner could not walk along
with the patient as he/she completed the task. Timing was stopped
when the lead foot crossed the finish line. The examiner then
recorded the subject’s walking time to within 0.1 second, rounding
up or down as necessary. We rounded up to the next tenth if the
hundredth of a second’s place was $.05, rounded down if the
hundredth of a second’s place was ,.05 (eg, 55.450 would round
up to 55.50 but 55.440 would round down to 55.40).
The mean walking speed (MWS) expressed in meters per second
were obviously calculated by dividing 7,62 m (i.e. 25 foot), 100 m
or 500 m by the time to perform the respective distances.
Comparisons between groups were made with a student t-test
and comparison within group with a paired t-test. All statistical
tests were applied with a two-tailed analysis and 0.05 as a level of
significance and were performed using GraphPad Prism, version
4.0b for Macintosh, GraphPad Software, San Diego California
USA (www.graphpad.com).
Results
The baseline characteristics of healthy control volunteers and
pMS are detailed in Table 1. The distributions of gender and
weight were comparable in both groups. The MS population was
well balanced between different ranges of clinical disability
stratified from EDSS 0 to 2.0, 2.5 to 3.5 and 4.0 to 6.0. Sixty
percent of our MS population had an unlimited walking range
defined by a MrWD$4000 m, whereas approximately 40%
reported to be able to walk between 500 m and 4000 m. MS
patients were also stratified according to pyramidal, cerebellar and
sensitive Kurtzke FS scores (all FS#1, FS=2 or FS=3, no
patients had an FS.3 in one of these three systems).
Mean timed performances in the 4 walking tests for healthy
volunteers and for the different subgroups of pMS are presented in
Table 2. For the T500MW, lap times per 100 m are also presented
(Table 2). The mean walking speed (MWS) was compared
between the 4 tests (Figure 1) in healthy volunteers and pMS
according to their EDSS and MrWD. In healthy volunteers and in
all subsets of pMS regardless of their EDSS or MrWD status, the
order of calculated MWS values was T25FW
+.T100MW.
T25FW.T500MW. In all short and longer distance walking tests,
the MWS was significantly lower for each subset of the pMS
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graphically in Fig. 1A and 1B for pMS with EDSS#2.0 or an
apparently unlimited MrWD$4000 m). MWS was also signifi-
cantly lower for pMS at EDSS 4.0–6.0 compared to EDSS 2.5–
3.5, in the 4 walking tests (Figure 1A, p,0.001 for all
comparisons). No significant difference was found between the
MWS of the pMS at EDSS 0–2.0 compared to EDSS 2.5–3.5
(p=0.1419 for T25FW, p=0.1987 for T25FW
+, p=0.1178 for
T100MW, and p=0.0783 for T500MW). Finally, MWS was
significantly higher for pMS with an MrWD$4000 m compared
to that of patients with an MrWD,4000 m in the 4 walking tests
(Figure 1B, p,0.001 for all comparisons). When pMS were
stratified according to pyramidal, cerebellar and sensitive Kurtzke
FS scores, MWS data for all walking tests were very sensitive to
detect significant differences between pMS with all FS#1 and
pMS with at least one FS=2 or to detect significant differences
between pMS with one FS=2 and pMS with the same FS=3
(Table S1).
In the T500MW, MWS was calculated over the five successive
100 m interval laps in order to capture the motor fatigue related
deceleration occurring over time during this demanding motor
task (Table 2, Figure 2). Different patterns of MWS evolution were
observed in regard of the type of population studied (Figure 2).
Regardless of the absolute differences of their MWS, healthy
volunteers and pMS with a low level of disability (i.e. with an
EDSS#2.0, MrWD$4000 m or all FS scores #1, Figure 2A, 2B
and 2C, D, E, respectively) significantly decelerated during a
500 m walking task, as demonstrated by the comparison between
the MWS of the first 100 m (T0–100MW) and the MWS of the
last 100 m (T400–500MW) during the test (p=0,0104 for healthy
volunteers, p,0,0001 for pMS with MrWD$4000 m and
p=0,0089 for pMS will all FS scores #1). A mild acceleration
at the end of the task (i.e. a higher MWS during the last 100 m -
T400–500 - compared to the MWS over the T300–400) was
observed in healthy volunteers and pMS with all FS scores #1, but
only reached significance in the healthy volunteers population
(p=0,0286, data not shown). A highly significant deceleration was
consistently observed in more disabled pMS with an EDSS 2.5–
3.5 and 4.0–6.0 (Figure 2A), a MrWD between 500 and 4000 m
(Figure 2B) or Kurtzke FS scores at 2 or 3 in the pyramidal,
cerebellar or sensitive systems (Figure 2C, 2D and 2E, respective-
ly). For these latter more disabled pMS groups all p values were
,0,0001 for the comparisons of MWS between T0–100MW and
T400–500MW.
In order to quantify ambulation fatigability over a demanding
distance of effort, we proposed to integrate the fastest and the
lowest measurable walking speeds over the different tested walking
paradigms. The T25FW
+ MWS was previously confirmed to be a
valid test to approach the fastest MWS of MS patients on a very
short distance regardless of their acceleration capacity [10]. On
the other hand, the mean finishing pace during the last 100 m of
the T500MW (T400–500MW) appeared to be the lowest
measurable speed over this fatigue inducing longer distance
(Figure 2). The difference between T25FW
+ MWS and T400–
500MW MWS was obviously significant in all pMS subgroups and
healthy volunteers (Figure 3A, all p,0,0001). The individual
performances of pMS showed that the relative deceleration
observed between MWS values of the T25FW
+ and T400–
Table 1. Baseline characteristics of people with MS and healthy control volunteers.
pMS Healthy controls
Number 81 30
Age (years; mean ± SD) 40.16611.35 30.3610.4
Sex (female, %) 59 70
BMI
1 (mean ± SD) 23.7264.13 23.3363.37
MS type (CIS/RR/SP/PP
2,% ) 10.1/61.7/14.6/13.4 n.a.
Disease duration (years; mean ± SD) 9.7568.79 n.a.
EDSS
3 (median; range) 3.5 (0–6.0) n.a.
0–2.0 (n, %) 30, 37 n.a.
2.5–3.5 (n, %) 21, 25.9 n.a.
4.0–6.0 (n, %) 30, 37 n.a.
All FS
4#1( n ,% ) 21, 25.9 n.a.
FS Pyramidal=2, irrespective of other FS (n, %) 15, 18.5 n.a.
FS Cerebellar=2, irrespective of other FS (n, %) 18, 22.2 n.a.
FS Sensitive=2, irrespective of other FS (n, %) 34, 41.9 n.a.
FS Pyramidal=3, irrespective of other FS (n, %) 25, 30.9 n.a.
FS Cerebellar=3, irrespective of other FS (n, %) 31, 38.3 n.a.
FS Sensitive=3, irrespective of other FS (n, %) 15, 18.5 n.a.
MrWD
5
$4000 meters (n, %) 49, 60.5 n.a.
$500 meters; ,4000 meters (n, %) 32, 39.5 n.a.
1; Body Mass Index (kg/cm
2);
2: clinically isolated syndrome/relapsing-remitting/secondary progressive/primary progressive - progressive-relapsing;
3: Expanded Disability Status Scale;
4: Kurtzke Functionnal System Score;
5: Maximum reported Walking Distance.
doi:10.1371/journal.pone.0034744.t001
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+ MWS) was
highly variable at all levels of walking impairment (stratified
according to the T25FW, Figure 3B) and EDSS status (Figure 3C).
We calculated the so-called Deceleration Index (DI) as the ratio
between MWS of the T400–500MW divided by MWS of the
T25FW
+ (Figure 3D). Hence, the lower the DI ratio is, the more
pronounced the patients were subjected to fatigue-related decrease
of their walking pace over a long distance effort evaluated here by
the 500 m dash. We observed a non significantly lower DI for
pMS altogether compared to healthy controls (p=0,088). pMS
with an EDSS 4.0–6.0 had a significantly lower DI compared to
pMS with an EDSS#2.0 (p=0.045). Compared to pMS with
pyramidal, cerebellar and sensitive FS scores all #1, pMS with
pyramidal or cerebellar FS at 2 had a non significantly lower DI
(p=0.33 and p=0.42, respectively), whereas pMS with pyramidal
or cerebellar FS at 3 had a significantly lower DI (p=0.02 and
p=0.03, respectively). In contrast, pMS with a sensitive FS at 2 or
3 had a lower DI than pMS with all FS scores #1 but the
differences were not significant for both comparisons. The DI of
pMS subjects with a MrWD between 500 m and 4000 m was
significantly lower than for pMS with a MrWD$4000 m
(p=0.0044). Finally, in contrast to the differences measured over
absolute walking performances in short or long distance walking
tests, no significant differences were observed for DI values
between healthy volunteers and pMS with a low level of disability
(i.e. with an EDSS#2.0, MrWD$4000 m or all FS scores #1,
statistics not graphically shown on Figure 3D).
Discussion
This study evaluated the relative walking speed performances of
pMS compared to healthy volunteers on short and long distance
walking tests. The groups were well matched according to BMI
and sex ratio but the higher age in the pMS population compared
to healthy volunteers may have slightly influenced the observed
differences since the mean WS probably decreases with age [20].
All walking tests were performed in the ‘‘as fast as you can’’
configuration of the task in order to downsize motivational
interferences, which are probably more prominent in a ‘‘preferred
pace’’ modality [21].
Figure 1. Mean walking speed (MWS) in healthy volunteers and in different subgroups of the pMS population. The same general
pattern of MWS differences across the different walking paradigms is observed in every group (T25FW
+.T100MW.T25FW.T500MW). In the 4
walking tests, the MWS was significantly slower for each subset of the pMS population compared to healthy volunteers (all p,0,0001), including pMS
with a low level of disability according to their EDSS status (EDSS#2.0, A) or an apparently unlimited MrWD (MrWD$4000 m, B).
doi:10.1371/journal.pone.0034744.g001
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moderate disability and EDSS scores ranging up to 6.0, the
evaluation of walking capacities over 500 m was an achievable
goal, as long as assistive devices and short stops if needed were
allowed for the more disabled patients between EDSS 4.5 and 6.0.
The range of performances of our pMS population was globally in
line with that of previous studies evaluating walking speed on
similar distances [2,12,22].
The absolute performances of pMS obviously decreased
according to the EDSS score, but a significant ambulation
impairment was already seen on short and long distance in pMS
with mild disability, with an EDSS status #2.0 or a
MrWD$4000 m [16,23].
We observed various patterns of deceleration in the different
subsets of pMS over a 500 m walking task, regardless of absolute
timed performances. As previously described, healthy volunteers
and pMS with minimal disability (all FS scores #1, i.e.
EDSS#1.5) retained the ability to accelerate during the last
100 m of the 500 m task [2,12]. This final WS acceleration
referred to the comparison between the T400–500 and the T300–
400. However the mean WS of the T400–500 remained
significantly lower than the mean WS of T0–100 for all subgroups.
This observation is probably related to motivational issues (‘‘end of
the task’’ phenomenon), but it is striking that no final WS
acceleration was observed in more disabled pMS, which may
reflect the consequences of a more severe cognitive impairment or
the translation of an increased spasticity or both aspects. For pMS
with significant disability ranging from EDSS 2.0 to 6.0, the
finishing pace of the last 100 m of the T500MW was the slowest
measurable WS across the 4 walking tests. In contrast, the mean
WS on T25FW
+ with a propelled start provided the fastest
measurable WS in all pMS subgroups.
In order to assess locomotor fatigue, we identified the
deceleration index (DI) as a ratio between the minimal (T400–
500) and maximal (T25FW
+) measurable WS. The origin of
walking fatigability was not investigated in the current study, but it
is noteworthy that pMS with a value of 3 on pyramidal or
cerebellar FS scores demonstrated a significant alteration in the DI
whereas pMS with a value of 3 on sensitive FS score did not. The
individual DI of pMS were highly variable at all stages of walking
impairment and the mean DI was significantly lower only in pMS
with EDSS 4.0–6.0 or a maximum reported walking distance
#4000 m. The mean DI remained similar to healthy volunteers in
pMS with a low level of disability (i.e. with an EDSS#2.0,
MrWD$4000 m) while absolute walking performances on short
or long distance walking tests were all significantly abnormal in
these pMS subgroups at early disease stages.
These results indicate that the DI measures the alteration of a
sustained performance throughout a long demanding walking task,
which is not captured by conventional absolute WS measure-
ments, whether on a specific short or long distance, or in time-
based settings. Such findings are consistent with the previous
demonstration that motor fatigue is partially independent from
motor (pyramidal) weakness [2,24].
In regard of the usual 500 m MrWD delineated by the EDSS
calculation rules, this work suggested that a MrWD of 4000 m
may be a more reliable threshold to better discriminate between
‘‘fully ambulatory’’ (as termed by John F. Kurtzke) and
significantly limited pMS according to their walking performances.
Figure 2. MWS over five successive 100 m interval laps along the T500MW. Subgroup analysis are presented in healthy volunteers and in
different subgroups of the pMS population, stratified according to their EDSS (A), their maximum reported walking distance (MrWD) (B), and their
pyramidal (C), cerebellar (D) and sensitive (E) functional scores (FS). The dashed lines represent the comparison between the ‘‘baseline’’ MWS of the
first 100 m (T0–100MW) and the ‘‘final’’ MWS of the last 100 m (T400–500MW) for all subgroups. t-test values were *p,0.05, **p,0.01, ***p,0.0001.
doi:10.1371/journal.pone.0034744.g002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34744Although the 4000 m was chosen arbitrarily, a higher threshold
may have led to consider healthy untrained individuals as disabled.
It was outside the scope of the present cross-sectional analysis to
investigate the sensitivity to change of the walking tests and their
relevance in self-reported quality of life of pMS but it will be
prospectively addressed in a future study.
In conclusion, we provided evidence that sequential gait
evaluation over a 500 m distance is a valuable tool to measure
the decrease of WS over the duration of a demanding walking task.
The combination of short and long distance ‘‘as fast as possible’’
walking tests to assess a relative deceleration (DI) is a coherent
paradigm to allow a reliable measurement of locomotor fatigue.
Our data suggest that ambulation fatigability is at least partially
independent from absolute performances on a given distance,
which are abnormal early in MS, while the DI is altered later in
the disease course. The DI may be a sensitive tool to detect and
measure walking fatigability even though it is less sensitive than
absolute mean WS on short and long distances to detect early
walking impairment. Further work will be needed to clarify the
clinical relevance of such a new performance-based measurement.
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